These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15625120)

  • 1. Normal and oncogenic forms of the receptor tyrosine kinase kit.
    Lennartsson J; Jelacic T; Linnekin D; Shivakrupa R
    Stem Cells; 2005; 23(1):16-43. PubMed ID: 15625120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction by several KIT juxtamembrane domain mutations.
    Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
    Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Ali S; Ali S
    Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction via the stem cell factor receptor/c-Kit.
    Rönnstrand L
    Cell Mol Life Sci; 2004 Oct; 61(19-20):2535-48. PubMed ID: 15526160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
    Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
    Samayawardhena LA; Hu J; Stein PL; Craig AW
    Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation.
    Edling CE; Pedersen M; Carlsson L; Rönnstrand L; Palmer RH; Hallberg B
    Br J Haematol; 2007 Jan; 136(2):260-8. PubMed ID: 17156394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.
    Yuzawa S; Opatowsky Y; Zhang Z; Mandiyan V; Lax I; Schlessinger J
    Cell; 2007 Jul; 130(2):323-34. PubMed ID: 17662946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new twist in the transmembrane signaling tool-kit.
    Lemmon MA; Ferguson KM
    Cell; 2007 Jul; 130(2):213-5. PubMed ID: 17662934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.
    Kim SY; Kang JJ; Lee HH; Kang JJ; Kim B; Kim CG; Park TK; Kang H
    Biochem Biophys Res Commun; 2011 Jul; 410(2):224-8. PubMed ID: 21640708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors.
    Tabone-Eglinger S; Subra F; El Sayadi H; Alberti L; Tabone E; Michot JP; Théou-Anton N; Lemoine A; Blay JY; Emile JF
    Clin Cancer Res; 2008 Apr; 14(8):2285-94. PubMed ID: 18413817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting c-Kit mutations: basic science to novel therapies.
    Sattler M; Salgia R
    Leuk Res; 2004 May; 28 Suppl 1():S11-20. PubMed ID: 15036937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of Kit in disease and the application of pharmacogenetics.
    Akin C; Metcalfe DD
    J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
    Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
    J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.